Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion
Show Display Options
Rank Status Study
1 Active, not recruiting Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Conditions: Hepatocellular Carcinoma;   Non-Resectable Hepatocellular Carcinoma
Interventions: Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Doxorubicin-Eluting Beads;   Other: Laboratory Biomarker Analysis;   Drug: Mitomycin;   Other: Pharmacological Study;   Other: Placebo;   Drug: Sorafenib Tosylate

Indicates status has not been verified in more than two years